Published in Agents Actions on September 01, 1977
Chemical mediators of migraine: preclinical and clinical observations. Headache (2011) 0.84
Migraine in the era of precision medicine. Ann Transl Med (2016) 0.76
Pharmacological actions of the antihypertensive agent N-amidino-2-(2,6-dichlorophenyl)acetamide hydrochloride (BS 100-141). Arzneimittelforschung (1975) 2.72
Evidence for common pharmacological properties of [3H]5-hydroxytryptamine binding sites, presynaptic 5-hydroxytryptamine autoreceptors in CNS and inhibitory presynaptic 5-hydroxytryptamine receptors on sympathetic nerves. Naunyn Schmiedebergs Arch Pharmacol (1983) 1.43
Alpha-adrenoceptors, 5-hydroxytryptamine receptors and the action of dihydroergotamine in human venous preparations obtained during saphenectomy procedures for varicose veins. Naunyn Schmiedebergs Arch Pharmacol (1984) 1.15
Pharmacological studies on frozen stored canine saphenous veins and basilar arteries. Naunyn Schmiedebergs Arch Pharmacol (1986) 1.07
The effect of ergotamine on humoral and neuronal actions in the nictitating membrane and the spleen of the cat. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol (1968) 1.04
Studies on the peripheral mode of action of dihydroergotamine in human and canine veins. Eur J Pharmacol (1974) 1.03
Evidence for mediation by 5-HT2 receptors of 5-hydroxytryptamine-induced contraction of canine basilar artery. Naunyn Schmiedebergs Arch Pharmacol (1983) 1.02
Investigations on the mode of action of ergotamine in the isolated femoral vein of the dog. Br J Pharmacol (1974) 1.00
Responsiveness of isolated canine cerebral and peripheral arteries to ergotamine. Naunyn Schmiedebergs Arch Pharmacol (1976) 0.99
The mechanism of ergometrine-induced coronary arterial spasm: in vitro studies on canine arteries. J Cardiovasc Pharmacol (1980) 0.97
Agonist potencies of tryptamine derivatives at pre- and postjunctional receptors in canine saphenous vein. Postgrad Med J (1981) 0.90
Characterization of the adenosine receptor in porcine coronary arteries. Br J Pharmacol (1990) 0.87
Cryopreservation: a useful technique for storing tissues for pharmacological investigations. Trends Pharmacol Sci (1988) 0.86
Vascular effects of ergot alkaloids: a study on human basilar arteries. Gen Pharmacol (1983) 0.86
What is known about the action of dihydroergotamine on the vasculature in man? Int J Clin Pharmacol Ther Toxicol (1984) 0.85
Tissue specific susceptibility of alpha-adrenoceptor mediated vasoconstriction to nifedipine. Naunyn Schmiedebergs Arch Pharmacol (1983) 0.84
The preservation of functional activity of smooth muscle and endothelium in pig coronary arteries after storage at -190 degrees C. J Pharm Pharmacol (1990) 0.84
[Diagnosis and etiology of aseptic femoral head necrosis in adults]. Z Orthop Ihre Grenzgeb (1970) 0.83
In vitro effects of calcium antagonists PN 200-110, nifedipine, and nimodipine on human and canine cerebral arteries. J Cereb Blood Flow Metab (1983) 0.82
Pharmacological actions of the main metabolites of dihydroergotamine. Eur J Clin Pharmacol (1984) 0.82
Functional studies on human veins after storage at--190 degrees C. Br J Pharmacol (1986) 0.82
Maintenance of functional activity of human pulmonary arteries after cryopreservation. Br J Pharmacol (1991) 0.81
Enhanced prostaglandin synthesis contributes to the venoconstrictor activity of ergotamine. Blood Vessels (1975) 0.81
Methylergometrine, an active metabolite of methysergide. Cephalalgia (1986) 0.80
2-[125Iodo]LSD, a new ligand for the characterisation and localisation of 5-HT2 receptors. Naunyn Schmiedebergs Arch Pharmacol (1984) 0.80
Dihydroergotamine: pharmacokinetics, pharmacodynamics, and mechanism of venoconstrictor action in beagle dogs. J Cardiovasc Pharmacol (1987) 0.80
Evidence for stimulation of 5-HT receptors in canine saphenous arteries by ergotamine. Naunyn Schmiedebergs Arch Pharmacol (1976) 0.80
Effects of calcium channel blockade in canine saphenous veins after storage at -190 degrees C. Br J Pharmacol (1988) 0.79
In vitro studies on the duration of action of dihydroergotamine. Int J Clin Pharmacol Ther Toxicol (1980) 0.79
Heterogeneity of 5-HT receptor subtypes in isolated human femoral and saphenous veins. Naunyn Schmiedebergs Arch Pharmacol (1993) 0.79
The recording of venous compliance in the conscious dog: a method for the assessment of venoconstrictor agents. J Pharmacol Methods (1984) 0.78
Ex vivo studies after oral treatment of the beagle with dihydroergotamine. Eur J Pharmacol (1983) 0.78
Studies on the mechanism of the venoconstrictor activity of ergotamine on isolated canine saphenous veins. Blood Vessels (1974) 0.78
[Pharmacology, pharmacokinetics and toxicology of the new antihistaminic HS 592 (Tavegil)]. Boll Chim Farm (1967) 0.78
Computer-aided calculation of the molecular size of nondenatured proteins in pore-gradient gel electrophoresis. Electrophoresis (1991) 0.78
Pizotifen, an antimigraine drug with venoconstrictor activity in vivo. J Cardiovasc Pharmacol (1986) 0.78
Nature of the vehicle solution for cryopreservation of human peripheral veins: preservation of reactivity to pharmacological stimuli. Cryobiology (1995) 0.77
Evidence for preservation of epithelial function in cryopreserved porcine and human bronchi. Exp Physiol (1994) 0.77
Cyclosporine and the renin-angiotensin system. Kidney Int Suppl (1991) 0.76
Pharmacologic studies on the structure-activity relationship of hydroxyindole alkylamines. Adv Pharmacol (1968) 0.76
Protecting the endothelial integrity of internal thoracic arteries. Thorac Cardiovasc Surg (2005) 0.76
[The action of ergotamine on humoral and neuronal effects in the nictitating membrane of the cat]. Helv Physiol Pharmacol Acta (1966) 0.75
Effects on arterial receptors of ergot derivatives used in migraine. Adv Neurol (1982) 0.75
Animal studies with topical steroids. Acta Derm Venereol Suppl (Stockh) (1973) 0.75
[Pharmacological, pharmacokinetic and toxicological research on mesoridazine (NC 123)]. Boll Chim Farm (1967) 0.75
[Pharmacological studies on the new antihistaminic Tavegil]. Med Welt (1966) 0.75
[Aminoalcohol esters of hydroxyboranes. 10. Tetracycline boron Mannich bases as potential antineoplastic agents]. Arch Pharm (Weinheim) (1984) 0.75
Proceedings: Further studies on the mode of action of ergotamine on canine vein strips. Naunyn Schmiedebergs Arch Pharmacol (1974) 0.75
[The problem of toxicity in pharmaceutical industries]. Bibl Tuberc (1969) 0.75
Proceedings: Differentiation between serotonin-and alpha-adrenoceptor blocking agents in isolated canine saphenous arteries. Naunyn Schmiedebergs Arch Pharmacol (1975) 0.75
Actions of co-dergocrine mesylate and its components at vascular smooth muscle. Naunyn Schmiedebergs Arch Pharmacol (1982) 0.75
[Derivatives of D-glucosamine. 12. Reactions of 2-acylamido-1,3,4,6-tetra-o-benzoyl-2-desocy-alpha-D-glucopyranoses with hydrogen bromide]. Carbohydr Res (1973) 0.75
Unchanged venoconstrictor activity of locally synthesized prostaglandins in grafts. Eur J Pharmacol (1979) 0.75
On the pharmacology of venous smooth muscle from dog and man. Folia Haematol Int Mag Klin Morphol Blutforsch (1979) 0.75
Comparison of the actions of serotoninergic agents on human saphenous veins and platelets. Eur J Pharmacol (1986) 0.75
[Influence of ergotamine on humoral and neuronal effects in the cat nictitating membrane and spleen]. Helv Physiol Pharmacol Acta (1967) 0.75
Studies on the 5-HT receptor in vascular smooth muscle. Res Clin Stud Headache (1978) 0.75